Bortezomib in combination with gemcitabine (GEM) and cisplatin (CDDP) in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC): A Hellenic Oncology Research Group multicenter phase II study.
Sofia Agelaki
No relevant relationships to disclose
Athanasios Kotsakis
No relevant relationships to disclose
Emmanouil Kontopodis
No relevant relationships to disclose
Nikolaos K. Kentepozidis
No relevant relationships to disclose
Konstantinos N. Syrigos
No relevant relationships to disclose
Nikolaos Ziras
No relevant relationships to disclose
Georgia Filippa
No relevant relationships to disclose
Lampros Vamvakas
No relevant relationships to disclose
Dimitrios Mavroudis
No relevant relationships to disclose
Vassilis Georgoulias
Consultant or Advisory Role - Amgen; Novartis; Pfizer
Research Funding - GlaxoSmithKline; Sanofi